Myoview 0.23 mg Powder For Solution is a Health Canada–registered radiopharmaceutical drug (DIN 02328755) held by Ge Healthcare Canada Inc, containing Tetrofosmin. Health Canada lists its status as Marketed (status date 27 Nov 2018). Nexara Health has matched 15 registrations of Tetrofosmin across 12 other regulated markets, 1 of them in the same strength and dosage form.
Health Canada registration
| DIN | 02328755 |
|---|---|
| Brand name | Myoview |
| Active ingredient | Tetrofosmin |
| Strength | 0.23 mg |
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Company | Ge Healthcare Canada Inc |
| Status | Marketed — 27 Nov 2018 |
| Class | Radiopharmaceutical |
| ATC | V09GA02 TECHNETIUM (99m Tc) TETROFOSMIN |
| AHFS | 36:68.00 |
| Regulator record | Health Canada DPD entry · Product monograph |
Tetrofosmin registered in other markets
15 registrations of the same molecule in 12 national registries outside Canada. Each row is taken from the regulator's own published list; status is shown as the registry reports it.
| Country | Product | Marketing authorisation holder | Strength | Form | Status | Registry |
|---|---|---|---|---|---|---|
| Bulgaria | Myoview | GE Healthcare AS | 0.23 mg kit for radiopharmaceutical preparation | прах за разтвор за инж. | По лекарско предписание | BDA |
| Czech Republic | Myoview | — | 230MCG | Rad Kit | R | SUKL DLP |
| Denmark | Myoview | GE Healthcare AS | 230 mikrogram | radiofarmaceutisk præparationssæt | MRP | Laegemiddelstyrelsen |
| Hong Kong | Myoview For Inj | Ge Medical Systems Hong Kong Limited | Registered | DH Drug Office | ||
| Iceland | Myoview (N186) | Icepharma - óskráð | stl | 0 | Lyfjastofnun lyfjaverdskra | |
| Ireland | MYOVIEW 230 micrograms kit for radiopharmaceutical preparation | GE Healthcare AS | Kit for radiopharmaceutical preparation | Not marketed | HPRA | |
| Malaysia | Myoview Powder For Injection | Alatan Teknologi Sdn. Bhd. | New Chemical Entity | PRODUCT APPROVED | NPRA | |
| Malta | MYOVIEW 230 micrograms kit for radiopharmaceutical preparation lyophilisate for sol for injection | GE Healthcare AS | Kit For Radiopharmaceutical Preparation, Solution For Injection | Authorised | Medicines Authority | |
| Netherlands | Myoview 230 microgram kit voor radiofarmaceutisch preparaat | GE Healthcare B.V. | Kit voor radiofarmaceutisch preparaat | Uitsluitend recept | EU national register | |
| Singapore | MYOVIEW FOR INJECTION 0.23 mg/vial | Ge Healthcare Pte. Ltd. | 0.23 mg/vial | Injection, Powder, For Solution | Prescription Only | HSA |
| Taiwan | Kit For Preparation Of 99mtc-Tetrofosmin "Myoview" | Ge Healthcare Limited | 注射劑 | 已註銷 | TFDA | |
| Taiwan | Myoview. Kit for radiopharmaceutical preparation. Powder for solution for injection | Ge Healthcare As | 凍晶乾燥注射劑 | Registered | TFDA | |
| United States | Myoview | Medi-Physics Inc. dba GE Healthcare | Injection, Powder, Lyophilized, For Solution | listed | FDA NDC | |
| United States | Myoview | Medi-Physics Inc. dba GE Healthcare | Injection, Powder, Lyophilized, For Solution | listed | FDA NDC | |
| United States | Tetrofosmin | GE Healthcare Lindesnes | Powder | FDA NDC |
See every manufacturer of Tetrofosmin worldwide →
Regulator price references for Tetrofosmin
Published list or reimbursement prices for Tetrofosmin presentations, in local currency, as at the date each registry last published. These are public reference prices, not Nexara Health quotes; strength and pack differ by row.
| Country | Product | Strength | Pack | Price | Type | Source | As of |
|---|---|---|---|---|---|---|---|
| Iceland | Myoview (N186) | hgl | 120,525.00 ISK | max wholesale | Lyfjastofnun lyfjaverdskra | 2026-09-02 |
Marketed Canadian products with the same active ingredient
| DIN | Product | Company | Strength | Form |
|---|---|---|---|---|
| 02422158 | Myoview 30ml | Ge Healthcare Canada Inc | 1.38 mg | Powder For Solution |
Related molecules (ATC V09GA)
Sourcing through Nexara Health
Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. Because this DIN is marketed in Canada, supply normally comes through the Canadian channel; where the Canadian presentation is short or discontinued, the registrations above show which regulated markets hold an equivalent that can be imported under the Special Access Programme or for clinical comparator use. Request a quote or read how named-patient and foreign-pack supply works in Canada.
Frequently asked questions
Is Myoview (DIN 02328755) marketed in Canada?
Yes. Health Canada lists DIN 02328755 as Marketed as of 27 Nov 2018.
Who holds the Canadian licence for this product?
Ge Healthcare Canada Inc is the company of record in the Health Canada Drug Product Database.
Is Tetrofosmin registered outside Canada?
Yes — Nexara Health has matched 15 registrations in 12 other markets, including 1 in the same strength and dosage form (see the table above).
Where does this data come from?
Health Canada Drug Product Database (DPD), DIN 02328755, status date 2018-11-27; national medicine registries: BDA, DH Drug Office, EU national register, FDA NDC, HPRA, HSA, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, Medicines Authority, NPRA, SUKL DLP, TFDA; price sources: Lyfjastofnun lyfjaverdskra. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.
Source: Health Canada Drug Product Database (DPD), DIN 02328755, status date 2018-11-27; national medicine registries: BDA, DH Drug Office, EU national register, FDA NDC, HPRA, HSA, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, Medicines Authority, NPRA, SUKL DLP, TFDA; price sources: Lyfjastofnun lyfjaverdskra.
Health Canada Drug Product Database (DPD), DIN 02328755, status date 2018-11-27; national medicine registries: BDA, DH Drug Office, EU national register, FDA NDC, HPRA, HSA, Laegemiddelstyrelsen, Lyfjastofnun lyfjaverdskra, Medicines Authority, NPRA, SUKL DLP, TFDA; price sources: Lyfjastofnun lyfjaverdskra. Last reviewed 2026-09-16. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.